Skip to main content

Table 3 Local recurrence-free survival and distant metastasis-free survival analyses for training and internal validation cohorts

From: Prognostic value of estrogen receptor-α and progesterone receptor in curatively resected colorectal cancer: a retrospective analysis with independent validations

  LRFS (HR, 95%CI, p value) DMFS (HR, 95%CI, p value)
Training set Internal validation set Training set Internal validation set
Univariate analysis
 ER-α
  High vs. low 6.63 (2.02–21.77), < 0.001* 1.85 (0.73–4.69), 0.174 6.79 (2.07–22.29), < 0.001* 1.346 (0.822-2.203), 0.329
Multivariate analysis
 Age
  > 60y vs. ≤60y 0.40 (0.11–1.49), 0.170 0.70 (0.30–1.62), 0.444 0.28 (0.07–1.09), 0.067 0.94 (0.63–1.40), 0.914
 Gender
  Female vs. male 0.63 (0.16–2.47), 0.503 0.94 (0.41–2.18), 0.892 1.56 (0.43–5.70), 0.497 1.20 (0.80–1.79), 0.373
 Stage
  Stage II- III vs. I 3.61 (1.12–11.65), 0.032* 1.09 (0.64–1.87), 0.196 3.56 (1.11–11.39), 0.032* 1.33 (1.02–1.73), < 0.001
 Localization
  Rectum vs. colon 0.94 (0.26–3.44), 0.926 0.30 (0.10–0.89), 0.028 0.69 (0.20–2.35), 0.552 1.50 (0.92–2.24), 0.076
 ER-α
  High vs. low 8.66 (2.24–33.41), 0.002* 1.71 (0.67–4.35), 0.285 6.61 (1.85–23.60), 0.004* 1.30 (0.79–2.13), 0.451
  1. Uni- and multivariate survival analyses. Hazard ratios were calculated by the adjusted Cox proportional hazards model
  2. Abbreviations: ER-α estrogen receptor -α
  3. *statistically significant
\